56.03

0.25% -0.14

Pre-market: 55.96 -0.07 -0.12%

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $56.03, with a volume of 1.53M. It is down -0.25% in the last 24 hours and up +29.40% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$56.17

Open:

$56.41

24h Volume:

1.53M

Relative Volume:

0.57

Market Cap:

$8.77B

Revenue:

$1.21B

Net Income/Loss:

$109.52M

P/E Ratio:

80.48

EPS:

0.6962

Net Cash Flow:

$269.60M

1W Performance:

+2.98%

1M Performance:

+29.40%

6M Performance:

-2.45%

1Y Performance:

+8.52%

1-Day Range:

$55.53

$56.96

1-Week Range:

$51.97

$56.96

52-Week Range:

$43.20

$72.16

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2026-08-05

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	56.03	8.79B	1.21B	109.52M	269.60M	0.6962
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

Jun 15, 2026

Bio-Techne (TECH) Stock Valuation After New Refeyn Bispecific Antibody Analysis Collaboration - Yahoo Finance

Jun 15, 2026

Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch

Jun 15, 2026

Bio-Techne (TECH) Gains 4% as Activist Investor Pushes for Strat - GuruFocus

Jun 15, 2026

Bio-Techne gains on report activist investor Ananym pushing for sale - Seeking Alpha

Jun 15, 2026

Bio-Techne stock rises as activist pushes for sale By Investing.com - Investing.com India

Jun 15, 2026

Activist Investor Ananym Urges Bio-Techne to Consider Selling - Bloomberg

Jun 15, 2026

Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers - Insider Monkey

Jun 15, 2026

Jun 13, 2026

Why is Techne (TECH) up 4.5% since last earnings report? - MSN

Jun 13, 2026

Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now? - Yahoo Finance

Jun 13, 2026

Jun 11, 2026

Bio-Techne Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Jun 11, 2026

TECH Initiates Coverage On Bio-Techne -- Price Target Announced at $65 - GuruFocus

Jun 11, 2026

Piper Sandler initiates Bio-Techne stock with neutral rating By Investing.com - Investing.com Nigeria

Jun 11, 2026

Piper Sandler initiates Bio-Techne stock with neutral rating - Investing.com

Jun 11, 2026

Jun 10, 2026

Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 10, 2026

Jun 08, 2026

New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH) - Yahoo Finance

Jun 08, 2026